Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults

首次发布于 2024 年 8 月 22 日

Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years

计划入组 25 人 · 首次发布于 2023 年 11 月 14 日

Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines

计划入组 400 人 · 首次发布于 2023 年 8 月 2 日

CX-038839 Omicron (XBB.1.5)(Spikevax)

Raxtozinameran

RQ-3033

CanSino Biologics Inc.

China

Micron Technology

Micron Biomedical, Inc.

United States

Pfizer and BioNTech's Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive CHMP Opinion

Pfizer and BioNTech Submit EMA Application for Updated COVID-19 Vaccine Targeting LP.8.1 Strain for 2025-2026 Season

Australian Researchers Develop Pan-Coronavirus Vaccine Candidate with 99.9% Protection Against Multiple Variants